Paper36923874
Paxillin is a potential prognostic biomarker associated with immune cell infiltration in ovarian cancer.
Meng LQ and 2 others. Heliyon, 2023. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Paxillin is a potential prognostic biomarker associated with immune cell infiltration in ovarian cancer. Papers, record 36923874. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36923874
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Paxillin is a potential prognostic biomarker associated with immune cell infiltration in ovarian cancer.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References43
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33803954 | Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33803954 | PubMed |
| 2 | 32354198 | The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32354198 | PubMed |
| 3 | 22658128 | Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22658128 | PubMed |
| 4 | 29232467 | Immunotherapy in ovarian cancer. | Ann Oncol | 2017 | https://conductscience.org/library/papers/29232467 | PubMed |
| 5 | 32686982 | LncRNA DLX6-AS1 Contributes to Epithelial-Mesenchymal Transition and Cisplatin Resistance in Triple-negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis. | Cell Transplant | 2020 | https://conductscience.org/library/papers/32686982 | PubMed |
| 6 | 33322675 | Regulation of Oncogenic Targets by the Tumor-Suppressive miR-139 Duplex (miR-139-5p and miR-139-3p) in Renal Cell Carcinoma. | Biomedicines | 2020 | https://conductscience.org/library/papers/33322675 | PubMed |
| 7 | 35968331 | CDC20 is a novel biomarker for improved clinical predictions in epithelial ovarian cancer. | Am J Cancer Res | 2022 | https://conductscience.org/library/papers/35968331 | PubMed |
| 8 | 23792636 | Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer. | Cancer Biol Ther | 2013 | https://conductscience.org/library/papers/23792636 | PubMed |
| 9 | 30917847 | Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. | J Ovarian Res | 2019 | https://conductscience.org/library/papers/30917847 | PubMed |
| 10 | 34743206 | NR1D1 regulation by Ran GTPase via miR4472 identifies an essential vulnerability linked to aneuploidy in ovarian cancer. | Oncogene | 2022 | https://conductscience.org/library/papers/34743206 | PubMed |
| 11 | 28756722 | The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review. | Expert Rev Anticancer Ther | 2017 | https://conductscience.org/library/papers/28756722 | PubMed |
| 12 | 32267026 | Investigation of pathology, expression and proteomic profiles in human TREM2 variant postmortem brains with and without Alzheimer's disease. | Brain Pathol | 2020 | https://conductscience.org/library/papers/32267026 | PubMed |
| 13 | 34135128 | Pan-cancer analysis reveals an immunological role and prognostic potential of PXN in human cancer. | Aging (Albany NY) | 2021 | https://conductscience.org/library/papers/34135128 | PubMed |
| 14 | 18468721 | DNA tumour viruses promote tumour cell invasion and metastasis by deregulating the normal processes of cell adhesion and motility. | Eur J Cell Biol | 2008 | https://conductscience.org/library/papers/18468721 | PubMed |
| 15 | 33327048 | Ovarian cancer risk score predicts chemo-response and outcome in epithelial ovarian carcinoma patients. | J Gynecol Oncol | 2021 | https://conductscience.org/library/papers/33327048 | PubMed |
| 16 | 29924724 | Down-regulated paxillin suppresses cell proliferation and invasion by inhibiting M2 macrophage polarization in colon cancer. | Biol Chem | 2018 | https://conductscience.org/library/papers/29924724 | PubMed |
| 17 | 36077735 | Molecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36077735 | PubMed |
| 18 | 35498135 | Mitochondrial Dysfunction Pathway Alterations Offer Potential Biomarkers and Therapeutic Targets for Ovarian Cancer. | Oxid Med Cell Longev | 2022 | https://conductscience.org/library/papers/35498135 | PubMed |
| 19 | 33686968 | A bioinformatic analysis: the overexpression and clinical significance of FCGBP in ovarian cancer. | Aging (Albany NY) | 2021 | https://conductscience.org/library/papers/33686968 | PubMed |
| 20 | 31967683 | Biomarkers in ovarian cancer: To be or not to be. | Cancer | 2019 | https://conductscience.org/library/papers/31967683 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42465974 | Prognostic biomarkers for enhanced risk stratification in extraskeletal myxoid chondrosarcoma: a retrospective cohort study. | PeerJ | 2026 | https://conductscience.org/library/papers/42465974 | PubMed |
| 42192404 | TRIM15 Mediates ubiquitination of Paxillin to facilitate the progression of ovarian cancer. | Cancer Cell Int | 2026 | https://conductscience.org/library/papers/42192404 | PubMed |
| 41872167 | Deciphering the STAT3-PXN positive feedback loop in GBM, IDH-wildtype: transcriptional regulation and inhibition of YB-1 ubiquitination. | Cell Death Discov | 2026 | https://conductscience.org/library/papers/41872167 | PubMed |
| 40271988 | Mechanometabolism: recent findings on the intersection of cell adhesion, cell migration, and metabolism. | Am J Physiol Cell Physiol | 2025 | https://conductscience.org/library/papers/40271988 | PubMed |
| 40045379 | Focal adhesion in the tumour metastasis: from molecular mechanisms to therapeutic targets. | Biomark Res | 2025 | https://conductscience.org/library/papers/40045379 | PubMed |
| 40001476 | Paxillin and Kindlin: Research Progress and Biological Functions. | Biomolecules | 2025 | https://conductscience.org/library/papers/40001476 | PubMed |
Genes19
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36923874
GET https://conductscience.org/api/papers/v1/36923874/references?page=2